Cargando…

Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2

Relapse of disease and subsequent resistance to established therapies remain as major challenges in the treatment of multiple myeloma (MM). New therapeutic options are needed for these extensively pretreated patients. To explore an optimized combinational therapy, interactions between the irreversib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Lu, Gao, Minjie, Yang, Guang, Tao, Yi, Kong, Yuanyuan, Yang, Ruixue, Meng, Xiuqin, Ai, Gongwen, Wei, Rong, Wu, Huiqun, Wu, Xiaosong, Shi, Jumei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427084/ https://www.ncbi.nlm.nih.gov/pubmed/26000292 http://dx.doi.org/10.1155/2015/459052

Ejemplares similares

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I
por: Yang, Guang, et al.
Publicado: (2015)

Smoldering Multiple Myeloma
por: Gao, Minjie, et al.
Publicado: (2015)

Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma
por: Gao, Minjie, et al.
Publicado: (2016)

Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma
por: Liu, Liping, et al.
Publicado: (2016)

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
por: Kaufman, Jonathan L., et al.
Publicado: (2019)

Multiple myeloma cancer stem cells
por: Gao, Minjie, et al.
Publicado: (2016)

Panobinostat and Multiple Myeloma in 2018
por: Yee, Andrew J., et al.
Publicado: (2018)

Efficacy of Panobinostat for the Treatment of Multiple Myeloma
por: Eleutherakis-Papaiakovou, Evangelos, et al.
Publicado: (2020)

Ferroportin downregulation promotes cell proliferation by modulating the Nrf2–miR-17-5p axis in multiple myeloma
por: Kong, Yuanyuan, et al.
Publicado: (2019)

A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort
por: Berdeja, Jesus G., et al.
Publicado: (2021)

Panobinostat for the treatment of multiple myeloma: the evidence to date
por: Bailey, Hanna, et al.
Publicado: (2015)

Early versus Deferred Treatment for Smoldering Multiple Myeloma: A Meta-Analysis of Randomized, Controlled Trials
por: Gao, Minjie, et al.
Publicado: (2014)

Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019)

The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2022)

Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma
por: Gao, Minjie, et al.
Publicado: (2017)

Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo
por: Xie, Bingqian, et al.
Publicado: (2016)

Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
por: Gasparetto, Cristina, et al.
Publicado: (2021)

Carfilzomib-associated pulmonary arterial hypertension in multiple myeloma
por: Yang, Jenny Z., et al.
Publicado: (2021)

Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors
por: Bat-Erdene, Ariunzaya, et al.
Publicado: (2016)

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
por: Rosenthal, A, et al.
Publicado: (2016)

Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
por: Español, Ignacio, et al.
Publicado: (2017)

Optimizing carfilzomib use in multiple myeloma treatment
por: Yoon, Sung-Soo
Publicado: (2019)

The role of carfilzomib in relapsed/refractory multiple myeloma
por: Yee, Andrew J.
Publicado: (2021)

TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma
por: Tao, Yi, et al.
Publicado: (2017)

Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways
por: Bruzzese, F, et al.
Publicado: (2013)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Synergistic Tumor Cytolysis by NK Cells in Combination With a Pan-HDAC Inhibitor, Panobinostat
por: Afolabi, Lukman O., et al.
Publicado: (2021)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Targeted treatments for multiple myeloma: specific role of carfilzomib
por: Sugumar, Dhivya, et al.
Publicado: (2015)

Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells
por: Baranowska, Katarzyna, et al.
Publicado: (2016)

Carfilzomib boosted combination therapy for relapsed multiple myeloma
por: Steiner, Raphael E, et al.
Publicado: (2017)

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
por: Méndez-Toro, Arnold, et al.
Publicado: (2020)

Panobinostat Synergistically Enhances the Cytotoxicity of Microtubule Destabilizing Drugs in Ovarian Cancer Cells
por: Ovejero-Sánchez, María, et al.
Publicado: (2022)

PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ
por: Iwasa, Masami, et al.
Publicado: (2019)

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis
por: Facon, Thierry, et al.
Publicado: (2022)

Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma
por: Fostier, Karel, et al.
Publicado: (2012)

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
por: Badros, A Z, et al.
Publicado: (2013)

Acute Tubular Necrosis in a Patient With Myeloma Treated With Carfilzomib
por: Liberman, Vladimir, et al.
Publicado: (2016)

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma
por: Jain, Tania, et al.
Publicado: (2017)

Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma
por: Ikoma, Takenori, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rpvaeet1fpljhr3u9ao3s8462c